Intelligencia AI™

Intelligencia AI™ leads the way in leveraging proprietary data, biomedical expertise and artificial intelligence (AI) with its patented technology to address significant challenges in the pharmaceutical industry. These challenges include lengthy drug development timelines, excessive costs, and unsustainable return on investment (ROI). Its suite of AI-powered solutions delivers actionable insights crucial in mitigating risks and enhancing decision-making associated with drug development by providing an accurate, unbiased assessment of a drug's probability of success.

Founded in 2017, Intelligencia AI is headquartered in New York, NY, with offices in San Francisco, CA, and Athens, Greece, and employs 110 individuals globally.